GSK Commits $750M to Get Chimagen’s Phase 1-Ready Drug for Multiple Myeloma Read More September 15, 2026
The Real Bottleneck in U.S. Pharma Reshoring Isn’t Factories – It’s Talent Read More September 15, 2026
Scholar Rock Drug Wins First-in-Class Approval in Rare Neuromuscular Disease Read More September 14, 2026
Shadow AI Is the Fastest Growing Force in Medicine, and Hospitals Are the Only Ones Who Can Control It Read More September 14, 2026
From Onboarding to Outcomes: The Privacy-First Identity Workflow for Pharma Marketing Read More September 14, 2026